More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3% […]
Year: 2024
DB Endgame update Q3 2024
Discussing emerging issues and market activity in the DB Endgame space.
Benefit consulting excellence celebrated at WSB Awards
For the third consecutive year, we were named ‘Employee Benefits Consultant of the Year’ at the Workplace Savings and Benefits (WSB) awards.
Tackling the ethnicity pay gap
Are you ready for mandatory ethnicity pay gap reporting? Our video explains how we can help you to ensure compliance and create a fairer workplace.
How Narrow or Broad Are ACA Marketplace Physician Networks?
This report examines the share of doctors participating in the provider networks of Qualified Health Plans (QHPs) offered in the individual market in the federal and state Marketplaces in 2021, and how network breadth affected costs for enrollees.
KFF Analysis Finds Physician Networks in ACA Marketplace Plans Vary Widely, and Enrollees Typically Pay More in Premiums to Access Broader Networks
A KFF analysis of physician networks in the Affordable Care Act’s Marketplace plans finds wide variations in the share of local practicing physicians who participate, with the least costly plans generally having a smaller share of physicians than more expensive plans. The analysis examines the breadth of physician networks listed […]
How many people with employer-sponsored insurance use the drugs slated for Medicare price negotiations
A new KFF analysis examines the number of enrollees in the employer-sponsored insurance market who use one or more of the ten drugs selected for Medicare Part D price negotiations. Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the 10 drugs. […]
While Medicare Drug Price Negotiations Don’t Apply to Private Insurance, 3.4 Million People with Employer Coverage Take at Least One of the Selected Drugs
Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations.
Compare the Candidates on Health Care Policy
The side-by-side comparison tool provides a quick overview of former President Trump’s and Vice President Harris’ records, positions, public statements, and proposed policies on a range of key health care topics.
Marketplace Insurers are Proposing a 7% Average Premium Hike for 2025 and Pointing to Rising Hospital Prices and GLP-1 Drugs as Key Drivers of Costs
ACA Marketplace insurers are proposing a median premium increase of 7% for 2025, similar to the 6% premium increase filed for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers’ proposed rate changes – most of which fall between 2% and 10% – may change during […]